Downloads: 37

Files in This Item:
File Description SizeFormat 
j.jcyt.2022.10.005.pdf1.17 MBAdobe PDFView/Open
Title: Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation
Authors: Jo, Tomoyasu
Arai, Yasuyuki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-9662-5093 (unconfirmed)
Hatanaka, Kazuo
Ishii, Hiroyuki
Ono, Akiko
Matsuyama, Nobuki
Mori, Jumpei
Koh, Yangsook
Azuma, Fumihiro
Kimura, Takafumi
Author's alias: 城, 友泰
新井, 康之
Keywords: Cord-blood transplantation
Donor-specific anti-HLA antibodies
Engraftment
HLA-DP
HLA-DQ
Issue Date: Apr-2023
Publisher: Elsevier BV
Journal title: Cytotherapy
Volume: 25
Issue: 4
Start page: 407
End page: 414
Abstract: [Background aims] While donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) in the recipient before transplantation are associated with graft failure in cord-blood transplantation (CBT), effects of DSAs other than against HLA-A, -B or -DRB1 on transplantation outcomes remained poorly understood. [Methods] We retrospectively analyzed 567 single-unit CBT recipients to evaluate impact of DSAs against HLA-DP and -DQ on CBT outcomes. [Results] Among 143 recipients (25.2%) who had anti-HLA antibodies, nine harbored DSAs against HLA-DP or -DQ. DSAs against HLA-DP or -DQ were associated with a significantly lower neutrophil engraftment rate (55.6% versus 91.8%, P = 0.032) and with a marginally lower platelet engraftment rate (46.7% versus 75.3%, P = 0.128) at day 100 after transplantation, compared with patients without anti-HLA antibodies. Time to neutrophil and platelet engraftment in patients with DSAs for HLA-DP or -DQ was significantly longer than that in patients without anti-HLA antibodies (median, 25 versus 21 days, P = 0.002 in neutrophil; median 61 versus 46 days, P = 0.014 in platelet). Cumulative incidence of bacterial infection at day 100 was significantly greater (88.9% versus 57.1%, P = 0.024), and re-transplant-free survival was marginally lower (55.6% versus 76.8%, P = 0.132) in patients with DSAs against HLA-DP or -DQ, compared with those without anti-HLA antibodies. These findings suggest that DSAs against HLA-DP or -DQ lead to unfavorable engraftment, which may increase risk of bacterial infection, and reduce survival soon after CBT. [Conclusions] Our results suggest the importance of evaluating DSAs against HLA-DP and -DQ in recipients before selecting CB units.
Rights: © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license.
URI: http://hdl.handle.net/2433/282849
DOI(Published Version): 10.1016/j.jcyt.2022.10.005
PubMed ID: 36335019
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons